Glycomine
Glycomine is a clinical-stage biotechnology company developing treatments for rare diseases lacking therapeutic options. Its lead candidate, GLM101, is a mannose-1-phosphate replacement therapy for PMM2-CDG, a life-threatening genetic disorder. The therapy aims to restore pathway function by bypassing disease-causing mutations.
Buy Funded Startups lists
Funding Round: Series C
Funding Amount: $115M
Date: 16-Apr-2025
Investors: CTI Life Sciences Fund, funds managed by abrdn Inc., Advent Life Sciences, Novo Holdings, Sanofi Ventures, Abingworth, RiverVest Venture Partners, Sanderling Ventures, Chiesi Ventures, Remiges Ventures, Asahi Kasei Ventures
Markets: Biotechnology, Pharmaceuticals, Rare Diseases
HQ: San Francisco, California, United States
Founded: 2015
Website: http://www.glycomine.com/
LinkedIn: https://www.linkedin.com/company/glycomine-inc-
Twitter: https://twitter.com/GlycomineBio
Crunchbase: https://www.crunchbase.com/organization/glycomine
Leave a Comment
Comments
No comments yet.